The anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapies have revolutionized the treatment of metastatic and advanced-stage NSCLC (10, 11). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.